65,437 trials
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Type 1 Diabetes Mellitus
Primary: Change in Brachial Artery Diameter — -0.93 percentage of dilation
Melanoma
Primary: Progression Free Survival — 1.87; 2.04 years — p=0.76
Inflammatory Bowel Disease
Primary: Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74 — 88.5; 90.3 percentage of participants
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Endpoint is the Occurrence of Dose Limiting Toxicity (DLT). — 0; 0 participants
Asthma
Primary: Change in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average — 4.1; 17.8 liters/minute — p=<0.0001
Barrett Esophagus · Esophageal Cancer
Primary: Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus — 1.4; -14.7 percentage of change — p=0.7981
Neoplasms, Breast
Primary: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee…
Mantle Cell Lymphoma
Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants
Bipolar Disorder
Primary: Young Mania Rating Scale (YMRS) — 12.70; 12.57 units on a scale
Invasive Fungal Infections
Primary: The Rate of Invasive Fungal Infections — 77; 27 participants — p=0.007
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival at 6 Months — 20.6 percentage of participants
Meconium Ileus · Very Low Birth Weight Infant
Primary: Time to Complete Meconium Evacuation in Days — 7; 8 days of life — p=0.61
Ulcerative Colitis · Crohn's Disease
Primary: Number of Participants With Adverse Events (AEs) — 21; 35; 2; 9 participants